MedTrace Logo

Vancomycin Associated Red Man Syndrome (RMS)

NCT00824122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 544

Last updated 2011-10-12

No results posted yet for this study

Summary

This study proposes to identify patients who developed RMS with vancomycin infusion, and determine presence or absence of variant alleles involved in histamine biotransformation. The implications of this study are important, as identification of variant alleles in these patients, may alter the current standard of care for vancomycin infusions.

The hypothesis of this study is that the development of red man syndrome (RMS) during receipt of intravenous vancomycin is associated with the presence of variant alleles for genes involved in the histamine pathway. The primary outcome that will be measured will be the history of RMS and the presence or absence of variant alleles for the genes responsible for histamine metabolism (i.e. histamine n-methyltransferase and diamine oxidase). As a secondary endpoint, the study will also attempt to determine the incidence of RMS in pediatric patients.

Conditions

  • Red Man Syndrome

Sponsors & Collaborators

  • Katherine Berry Richardson Foundation

    collaborator UNKNOWN

  • Children's Mercy Hospital Kansas City

    lead OTHER

Principal Investigators

  • Angela Myers, MD, MPH · Children's Mercy Hosptials and Clinics

Eligibility

Min Age
6 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-12-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824122 on ClinicalTrials.gov